|Day's Range||31.58 - 31.67|
|52 Week Range||25.33 - 31.67|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.08%|
On January 6, 2017, Novartis announced the collaborative agreement with Ionis Pharmaceuticals (IONS) and its subsidiary Akcea Therapeutics.
Investors seeking low fees on developed markets exposure should look at this ETF.
[Editor’s Note: Due to a data error, an earlier version of this article suggested that the newly launched IDEV had taken over as the cheapest international developed-market equity ETF. In fact, the Schwab International Equity ETF (SCHF) remains the cheapest fund in that category, with an expense ratio of 0.06%. We apologize for the error, which has been corrected below.]